NewGenIvf Group Ltd (NASDAQ: NIVF)

NewGenIvf Group Ltd specializes in assisted reproductive services (ARS), offering a range of fertility treatments and related services across multiple countries. The company operates in the healthcare sector, focusing on solutions for infertility, including in vitro fertilization (IVF), surrogacy, and other reproductive technologies. Its operations span Thailand, Cambodia, and Kyrgyzstan, with a strong presence in the Asia-Pacific region.

NewGenIvf generates revenue through its fertility treatment services, which include IVF, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, freezing, and egg freezing. The company also offers surrogacy and ancillary caring services, as well as consultation services such as check-ups and blood tests. Its primary customer base consists of individuals and couples seeking fertility treatments, with a significant portion of clients originating from China, including mainland China and Hong Kong. The company also serves local patients in Thailand and Cambodia.

• Assisted Reproductive Services (ARS): NewGenIvf provides a comprehensive suite of ARS, including IVF, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening by Preimplantation Genetic Testing (PGT), hysteroscopy, sperm analysis, sorting, washing, and freezing. These services cater to individuals and couples facing infertility challenges, offering solutions to help them conceive. The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, providing localized services tailored to the needs of each market.

• Surrogacy and Ancillary Caring Services: In Kyrgyzstan, NewGenIvf offers surrogacy services, taking advantage of the country's favorable legal environment and relatively low costs for surrogate candidates. The company provides related ancillary services, including maternity care and documentation support, ensuring a comprehensive solution for clients. These services are designed to support the entire surrogacy process, from embryo transfer to postnatal care.

• Consultation Services: NewGenIvf also offers consultation services, which include check-ups, blood tests, and other minor services. These services cater to individuals who may require preliminary assessments or ongoing monitoring related to fertility treatments. The consultation services complement the company's core fertility treatments, providing a holistic approach to reproductive health.

NewGenIvf competes primarily with other regional fertility service providers. While the company does not believe any single competitor offers a comparably robust and integrated fertility solution package, it faces competition from providers that may offer better services, have established local connections, or fulfill evolving client needs. The company's competitive advantages include the value and comprehensiveness of its solutions, effective treatments that achieve desired outcomes, and a focus on client experience, including dedicated patient education, clinical guidance, and emotional support. Additionally, NewGenIvf provides access to a network of high-quality fertility specialists, further enhancing its competitive position.

The company's customer base is diverse, with a significant portion of clients coming from China, including mainland China and Hong Kong. The number of Thai and Cambodian local patients has generally increased in recent years due to the impact of COVID-19 on international travel. NewGenIvf enters into verbal contracts with each of its customers, outlining the scope of services, service fees, payment terms, and the rights, responsibilities, and obligations of each party. Consent is obtained from patients prior to the provision of various treatments, ensuring a clear understanding of the services and expectations.